Articles By Suzanne Elvidge

  1. Can Private Money Stop The Slump In Global R&D Funding? 2/7/2018

    A closer analysis of the Brookings Institute’s Private Sector Investment in Global Health R&D: Spending Levels, Barriers, and Opportunities report.

  2. Alternatives To Funding Lower-Priority Trials 8/9/2017

    While some pharma companies struggle to backfill their pipelines, others find the opposite, that they have more development opportunities than they can pursue. While this may seem to be a nice problem to have, it also means that otherwise good drug candidates may be pushed down the list of priorities.

  3. Bridging The Gap Between Academia, Small Biotechs, And Industry 6/7/2017

    Academia and biotech have long been sources of innovation for the pharmaceutical industry, and this is increasingly important for Big Pharmas that want to prop up flagging pipelines or boost particular areas of focus.